Impact BioMedical is an early-stage biotech company that develops and licenses proprietary technologies in human healthcare and wellness. The company's business model centers on building a patent portfolio, then licensing those technologies to pharmaceutical, consumer goods, and food companies in exchange for milestone payments and royalties. Impact BioMedical does not manufacture or sell products directly — its commercial partners handle development, manufacturing, and distribution. The company has four core technology platforms: Linebacker, a small-molecule compound platform targeting oncology, inflammatory disorders, and neurology; Equivir, a polyphenol blend with antiviral properties targeting upper respiratory wellness; Laetose, a patented sugar alternative targeting caloric and glycemic reduction; and 3F, a botanical-based functional fragrance platform with antimicrobial and insect-repellent applications. Linebacker and Equivir are licensed to ProPhase Laboratories for worldwide commercialization, making ProPhase Impact BioMedical's primary near-term revenue source. The company recently acquired Celios, an air purification technology company, signaling a broader intent to acquire technologies with more immediate direct revenue potential. Impact BioMedical operates with a minimal footprint of just two full-time employees, reflecting its IP-centric model. The company has a planned reverse merger with Dr. Ashleys Limited, a pharmaceutical manufacturer, which would combine Impact BioMedical's patent portfolio with Dr. Ashleys' manufacturing capabilities.